Glenmark Pharmaceuticals Inc., USA (Glenmark) has announced the upcoming launch of Leucovorin Calcium for Injection USP, 350 mg/vial Single-Dose Vial. 

Glenmark's Leucovorin Calcium for Injection USP, 350 mg/vial Single-Dose Vial is bioequivalent and therapeutically equivalent to the reference listed drug, Leucovorin Calcium for Injection, 350 mg/vial, of Hospira. Glenmark will begin distribution in December 2025. 

According to IQVIA sales data for the 12-month period ending October 2025, the Leucovorin Calcium for Injection, 350 mg/vial market2 achieved annual sales of approximately $16.8 million. 

Commenting on the launch, Marc Kikuchi, President & Business Head, North America said, "We are pleased to announce the upcoming launch of Leucovorin Calcium for Injection USP, 350 mg/vial Single-Dose Vial, further expanding our portfolio of products within the institutional channel, while also strengthening our commitment to bring to market quality and affordable alternatives for patients." 

Glenmark's Leucovorin Calcium for Injection USP, 350 mg/vial Single-Dose Vial is only approved for the indication(s) listed in Glenmark's approved label. 

Market includes brand and all available therapeutic equivalents. Note: IQVIA® data obtained by Glenmark is only available for all approved RLD indications. Glenmark's product is only approved for the indications listed in Glenmark's approved label and is not marketed for all RLD indications.